---
title: "HPGC's subsidiary plans to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240379069.md"
description: "HPGC's wholly-owned subsidiary, HPGC Sanjing Pharmaceutical Co., Ltd., intends to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan. After the acquisition, Sanjing Qianhe will become its wholly-owned subsidiary. This move will optimize resource allocation, improve industrial layout, enhance market competitiveness, and promote the company's high-quality development, aligning with the long-term development and interests of all shareholders"
datetime: "2025-05-15T12:21:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240379069.md)
  - [en](https://longbridge.com/en/news/240379069.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240379069.md)
---

# HPGC's subsidiary plans to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan

According to the announcement from HPGC (600664.SH), its wholly-owned subsidiary Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. (hereinafter referred to as "Sanjing Pharmaceutical") intends to acquire 42.82% of the equity held by three individuals in Harbin Pharmaceutical Group Sanjing Qianhe Pharmaceutical Co., Ltd. (hereinafter referred to as "the target company" or "Sanjing Qianhe"). After the acquisition, Sanjing Qianhe will become a wholly-owned subsidiary of Sanjing Pharmaceutical. The investment amount for this acquisition is 23.446 million yuan.

The traditional Chinese medicine business of Sanjing Qianhe is an important component of the company's traditional Chinese medicine sector. This equity acquisition will help the company further optimize resource allocation, improve industrial layout, and synergize with the company's existing advantageous markets and resources in terms of brand and product promotion, sales channels, etc., further enhancing the market competitiveness of the business segment, promoting the company's high-quality development, and aligning with the long-term development and interests of all shareholders

### Related Stocks

- [600664.CN](https://longbridge.com/en/quote/600664.CN.md)
- [562390.CN](https://longbridge.com/en/quote/562390.CN.md)

## Related News & Research

- [Are There Really 'No Bad Ideas' When It Comes To 'Saving Or Democracy'?](https://longbridge.com/en/news/286701120.md)
- [09:06 ETHarmony Comes to the Massachusetts State House as The Platters® Prepare Their Musical Love Letter to the World](https://longbridge.com/en/news/286918739.md)
- [Colombia's ELN rebels call three-day ceasefire for presidential election](https://longbridge.com/en/news/287072814.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [Apple Flavor to Buy NovoSana’s China Assets for Up to USD66 Million in Health Supplements Push](https://longbridge.com/en/news/287039106.md)